Solvias, an independent pharmaceutical testing and manufacturing company, has acquired Utrecht, Netherlands-based Cergentis, bolstering its platform of biologics and cell and gene therapy (CGT) testing solutions. According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more researchers leverage emerging genetic engineering techniques to develop complex, novel me...